Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23496730 | 0.84 | RAB9A (0.39) | NPC1RAB9AAHRKDM4ENPSR1 | |
| SCHEMBL21901580 | 0.79 | LCK (0.45) | DYRK1A | |
| SCHEMBL21839531 | 0.78 | NPC1 (0.39) | DYRK1ANPC1RAB9AAHRKDM4E | |
| SCHEMBL29937254 | 0.76 | ALDH1A1 (0.55) | CYP2C19NPC1RAB9AKDM4EGAA | |
| SCHEMBL25414681 | 0.74 | PDGFRB (0.35) | NPC1RAB9AAHRKDRKDM4E | |
| SCHEMBL29966867 | 0.74 | PDGFRB (0.35) | NPC1RAB9AAHRKDRKDM4E | |
| SCHEMBL21091402 | 0.71 | PDPK1 (0.49) | KDM4EGAAALDH1A1LMNAHTT | |
| SCHEMBL29885344 | 0.71 | PDPK1 (0.49) | KDM4EGAAALDH1A1LMNAHTT | |
| SCHEMBL19757207 | 0.71 | ALDH1A1 (0.50) | DYRK1ANPC1RAB9AKDM4ENPSR1 | |
| SCHEMBL21839593 | 0.71 | NPC1 (0.39) | NPC1RAB9AAHRKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-11731984-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-3886991-A1 | KRAS G12C INHIBITORS | Eli Lilly and Company (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210179633-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2021-06-17 | — | — | US | disclosed |
| WO-2021118877-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10968214-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020081282-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20200115375-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115375-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | DYRK1A 2011/4885HSD17B1 2847/4885HSD17B2 3606/4885 |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | KRAS, NRAS, GLS2 | DYRK1A 2266/4885HSD17B1 3796/4885HSD17B2 2993/4885 |
| US-11731984-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | DYRK1A 706/4885HSD17B1 3510/4885HSD17B2 3911/4885 |
| US-10968214-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | DYRK1A 2011/4885HSD17B1 2847/4885HSD17B2 3606/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | DYRK1A 1402/4885HSD17B1 4345/4885HSD17B2 4384/4885 |
| US-20210179633-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | DYRK1A 706/4885HSD17B1 3510/4885HSD17B2 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.